Transcept Pharmaceuticals, Inc. to Present at the 20th Annual Piper Jaffray Health Care ...( PT. RICHMOND Calif. Nov. 24 /- Tr...),Health
Navigation Links
Transcept Pharmaceuticals, Inc. to Present at the 20th Annual Piper Jaffray Health Care Conference
Date:11/24/2008
PT. RICHMOND, Calif., Nov. 24 /PRNewswire/ -- Transcept Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, announced today that Glenn A. Oclassen, President & Chief Executive Officer, is scheduled to present at the 20th Annual Piper Jaffray Health Care Conference in New York City on Tuesday, December 2, 2008 at 8:00 AM Eastern Time.
An audio webcast of the presentation will be available at http://www.piperjaffray.com/conferences. The replay of the presentation will be available for 30 days.
About Transcept Pharmaceuticals
Transcept Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the fields of psychiatry and sleep medicine. The lead Transcept product candidate, Intermezzo(R), is a sublingual low dose formulation of zolpidem that has been developed for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep. Phase 3 clinical trials have been completed for Intermezzo(R) and, on September 30, 2008, Transcept submitted a New Drug Application to the U.S. Food and Drug Administration.
For further information, please visit the company's website at: http://www.transcept.com.
Safe Harbor
This press release contains forward-looking statements for purposes of the
Private Securities Litigation Reform Act of 1995 (the "Act"). Transcept
disclaims any intent or obligation to update these forward-looking statements,
and claim the protection of the Safe Harbor for forward-looking statements
contained in the Act. Examples of such statements include, but are not limited
to, the expected benefits of Transcept product candidates. Such statement
'/>"/>
| SOURCE Transcept Pharmaceuticals Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. Transcept Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
2. Transcept Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
3. Transcept Pharmaceuticals to Present at Cowen and Companys 27th Annual Health Care Conference in Boston
4. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
5. Transcept Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
6. Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
7. Transcept Pharmaceuticals to Present at RBC Capital Markets 2007 Healthcare Conference
8. Transcept Pharmaceuticals to Present at 19th Annual Piper Jaffray Health Care Conference
9. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
10. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
11. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
Post Your Comments:
(Date:11/9/2009)...y, study finds, , , MONDAY, Nov. 9 (Hea...ug Plavix (clopidogrel) works about the same in wo...s has found. , "After this study, I can say we ...th this very important drug," said Dr. Jeffrey S. ...ew York University Langone Medical Center in New Y...
(Date:11/9/2009)...ditions are age-related, researchers say , ...urgery doesn,t appear to speed the progression of ...to a new study that challenges the belief that tre..., "Because both conditions are strongly age-rel...," wrote Li Ming Dong, of Stony Brook University S...
(Date:11/9/2009)... sexual function, study says, , , MON...ble to restore sexual function to rabbits with dam...ab and implanting it, a new study reports. , Th...s say the technique could one day be used to treat... able to show the tissue was able to integrate and...
(Date:11/9/2009)...s are often blamed for the increasing rates of chi...wever finds that 80% of people think that parents ... (PRWEB) November 9, 2009 -- If you th...d Australia’s obesity epidemic, think again....rs. A recent survey commissioned for Fitness.com....
(Date:11/9/2009)...ights positive influence of sports participation o... IL (Vocus) November 9, 2009 -- As people age frac...esearch has highlighted the importance of exercise...ues. However, a new study published in the Novembe...inary Approach reveals that there may be signific...
Breaking Medicine News(10 mins):Health News:No Gender Gap Found for Clot-Busting Drug 2Health News:No Gender Gap Found for Clot-Busting Drug 3Health News:Cataract Surgery Doesn't Worsen Macular Degeneration: Study 2Health News:Scientists Grow New Penile Tissue in the Lab 2Health News:Scientists Grow New Penile Tissue in the Lab 3Health News:Fitness.com.au Poll Finds 80% Blame Parents For Our Overweight Kids 2Health News:High Impact Sports Participation May Improve Bone Mineral Density in Mature Athletes 2[0] No Gender Gap Found for Clot-Busting Drug[0] Cataract Surgery Doesn't Worsen Macular Degeneration: Study[0] Scientists Grow New Penile Tissue in the Lab[1] Fitness.com.au Poll Finds 80% Blame Parents For Our Overweight Kids[1] High Impact Sports Participation May Improve Bone Mineral Density in Mature Athletes
... Gay and lesbian civil partnerships (gay marriage)... benefits. Researchers said that such marriage lea...ariety of ways. // Civil partnerships for gay coup...the Journal of Epidemiology and Community Health s...
... Sudden Infant Death is thought to be spurred by t...ists from Bristol, England, have been able to asce...y of Bristol researchers have found certain sets o...ers.'
The research team, led by Professor Julia...
... The state government is facing accusation from th...f health services in the state. //
Reports are... a relapse within a month of being discharged from...alls, during the previous year. Apparently the gov...
... A new study published in the March 15, 2006 issue...n Cancer Society, says that the risk of a //new ca...ral breast cancer increases to a fair degree in wo...ith hereditary (non-BRCA) breast cancer greatly in...
... It has been proposed by the Jharkhand government ...mdev to exploit the potential of Ayurveda.// The y...y for manufacture and marketing of Ayurvedic medic... Ramdev next week when he arrives here for a yoga ...
... South East Asia has been long considered a wonder...bars, hotel lobbies or restaurants without any inh... the government is seriously thinking about imposi...nt offices, airports and other public venues like ...
Other Medicine News:Health News:Smoking Ban To Be Soon Implemented In South East Asian Bars 2Betterment Of Health In Case Of Gay And Lesbian Civil PartnershipsCauses of Sudden Infant Death ResearchedOpposition: Government turned a deaf ear to warnings about dwindling health care servicesHereditary Non-BRCA Breast Cancer Can Trigger New CancersYoga Guru Ramdev Invited to Tap Ayurveda Potential by Jharkhand Govt Smoking Ban To Be Soon Implemented In South East Asian Bars
(Date:11/9/2009)..., VIRGINIA BEACH, Va., Nov. 9 Lif...ny, announces the launch of Vertigraft Cervical Bi..., Preservon® is a new, proprietary glycero...t bio-implants to be stored in a fully hydrated st...ed to freeze or freeze-dry bio-implants, doing awa...
(Date:11/9/2009)..., MIAMI, Nov. 9 ISTA Ph...ced additional results from the Company,s Bepreve(...% Phase 3 clinical studies. These results were pr...ing of the American College of Allergy, Asthma &am...n a poster presentation titled, "Treatment of Ocul...
(Date:11/9/2009)..., WALTHAM, Mass., Nov. 9 Decision...d advisory firms for pharmaceutical and healthcare...th factor receptor 2 (HER2) targeting therapies --...mithKline/Nippon Kayaku,s Tykerb/Tyverb -- were th...tment. Continued uptake of Herceptin and Tykerb/Ty...
Breaking Medicine Technology:LifeNet Health Announces First Bio-Implant with New Preservation Technology 2ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) 2ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) 3Sales of HER2-Targeting Agents for Breast Cancer, Including Herceptin and Tykerb/Tyverb, Will Grow by 3.3 Percent Annually from 2008 to 2018 2Cyberonics Reports Strong Fiscal 2010 First Quarter Results 54925 1Cyberonics Reports Strong Fiscal 2010 First Quarter Results 54925 2Cyberonics Reports Strong Fiscal 2010 First Quarter Results 54925 3Cyberonics Reports Strong Fiscal 2010 First Quarter Results 54925 4Cyberonics Reports Strong Fiscal 2010 First Quarter Results 54925 5Cyberonics Reports Strong Fiscal 2010 First Quarter Results 54925 6Cyberonics Reports Strong Fiscal 2010 First Quarter Results 54925 7Cyberonics Reports Strong Fiscal 2010 First Quarter Results 54925 8Cyberonics Reports Strong Fiscal 2010 First Quarter Results 54925 9Cyberonics Reports Strong Fiscal 2010 First Quarter Results 54925 10Results In The New England Journal Of Medicine Confirm Novartis Drug Femara 28R 29 Is Superior To Tamoxifen After Breast Cancer Surgery 4872 1Results In The New England Journal Of Medicine Confirm Novartis Drug Femara 28R 29 Is Superior To Tamoxifen After Breast Cancer Surgery 4872 2Results In The New England Journal Of Medicine Confirm Novartis Drug Femara 28R 29 Is Superior To Tamoxifen After Breast Cancer Surgery 4872 3Results In The New England Journal Of Medicine Confirm Novartis Drug Femara 28R 29 Is Superior To Tamoxifen After Breast Cancer Surgery 4872 4Results In The New England Journal Of Medicine Confirm Novartis Drug Femara 28R 29 Is Superior To Tamoxifen After Breast Cancer Surgery 4872 5Results In The New England Journal Of Medicine Confirm Novartis Drug Femara 28R 29 Is Superior To Tamoxifen After Breast Cancer Surgery 4872 6Results In The New England Journal Of Medicine Confirm Novartis Drug Femara 28R 29 Is Superior To Tamoxifen After Breast Cancer Surgery 4872 7Results In The New England Journal Of Medicine Confirm Novartis Drug Femara 28R 29 Is Superior To Tamoxifen After Breast Cancer Surgery 4872 8Results In The New England Journal Of Medicine Confirm Novartis Drug Femara 28R 29 Is Superior To Tamoxifen After Breast Cancer Surgery 4872 9Medical Heroin Helps Treatment Resistant Addicts 54920 1Medical Heroin Helps Treatment Resistant Addicts 54920 2Medical Heroin Helps Treatment Resistant Addicts 54920 3[0] LifeNet Health Announces First Bio-Implant with New Preservation Technology[0] ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)[0] Sales of HER2-Targeting Agents for Breast Cancer, Including Herceptin and Tykerb/Tyverb, Will Grow by 3.3 Percent Annually from 2008 to 2018
...or Medical Use Approval and Insurance Coverage Var...OCHESTER, N.Y. - April 30, 2007-- Most U.S. adults...nd procedures that can,impact people,s quality of ... fertilization, drugs to treat erectile,dysfunctio... Large,majorities also believe these types of trea...
... N.Y.--(BUSINESS WIRE)--May 1, 2007 - Progenics,Ph... positive,results from the first clinical trial of... infected with the human immunodeficiency,virus (H...ng a,single 5.0 mg/kg dose of PRO 140 achieved an ...n the blood of 98.5% (1.83,log10), with individual...
Other Medicine Technology:Eighty-one Percent of U.S. Adults say that Birth Control Pills and,Procedures Should Be Covered by Health Insurance 2Eighty-one Percent of U.S. Adults say that Birth Control Pills and,Procedures Should Be Covered by Health Insurance 3Eighty-one Percent of U.S. Adults say that Birth Control Pills and,Procedures Should Be Covered by Health Insurance 4Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy 2Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy 3Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy 4Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy 5Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy 6Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy 7| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |